Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.56 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545000 | 1.00 | USP30 (0.58) | USP30GPR119SRD5A1CHEK2SRD5A2 | |
| SCHEMBL5544755 | 1.00 | USP30 (0.58) | USP30GPR119SRD5A1CHEK2SRD5A2 | |
| SCHEMBL1649132 | 0.92 | GPR119 (0.64) | USP30GPR119SRD5A1CHEK2SRD5A2 | |
| Hydrochloric Acid SCHEMBL14632585 | 0.91 | GPR119 (0.63) | USP30GPR119SRD5A1CHEK2SRD5A2 | |
| SCHEMBL15376733 | 0.90 | USP30 (0.54) | USP30GPR119SRD5A1CHEK2SRD5A2 | |
| SCHEMBL5548878 | 0.89 | GPR119 (0.55) | USP30GPR119CHEK2PIK3CDKMT2A | |
| SCHEMBL5548078 | 0.89 | GPR119 (0.55) | USP30GPR119CHEK2PIK3CDKMT2A | |
| SCHEMBL28716248 | 0.89 | GPR119 (0.55) | USP30GPR119CHEK2PIK3CDKMT2A | |
| SCHEMBL21409063 | 0.88 | USP30 (0.71) | USP30GPR119PIK3CDKMT2A | |
| SCHEMBL1769219 | 0.88 | USP30 (0.71) | USP30GPR119PIK3CDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163444-B | Chimeric compound for androgen receptor protein targeted degradation, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-114163444-A | Chimeric compound for targeted degradation of androgen receptor protein, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20170135994-A9 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160184282-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184281-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9193723-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9187472-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2847192-A1 | NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20130303508-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303511-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| EP-1031563-B1 | SULFONYL DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | USP30 3755/4885GPR119 3583/4885SRD5A1 282/4885 |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | USP30 2040/4885GPR119 162/4885SRD5A1 13/4885 |
| US-20130303508-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885SRD5A1 3018/4885 |
| US-20160184282-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885SRD5A1 3018/4885 |
| US-20130303511-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885SRD5A1 3018/4885 |
| US-20160184281-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885SRD5A1 3018/4885 |
| US-20030232808-A1 | Sulfonyl derivatives | SULT1E1, SULT2A1, SULT1A1 | USP30 3419/4885GPR119 215/4885SRD5A1 109/4885 |
| US-20170135994-A9 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | USP30 4391/4885GPR119 662/4885SRD5A1 3018/4885 |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD17B1 | USP30 2461/4885GPR119 182/4885SRD5A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.